Loading viewer...
earnings_deck
Format: PDF earnings_deck
Orexo's Q1 2018 Interim Report highlights a 26% growth in Zubsolv® in the US, providing insights for investors and stakeholders.
investor_presentation
earnings_deck
Vattenfall
earnings_deck
Cemig
earnings_deck
Adient
earnings_deck
R1 RCM